APAC Biotech Awarded Patent for Maturation and Production of Dendritic Cells as a Personalized Immunotherapy Treatment for Cancer

On July 23, 2020 APAC Biotech, an Indian biotechnology company involved in extensive research on personalized immunotherapy using dendritic cells for over a decade, reported that it was finally granted Indian patent (340947), entitled "COMPOSITION AND METHOD FOR PRODUCING ACTIVATED DENDRITIC CELLS" (Press release, APAC Biotech, JUL 23, 2020, View Source [SID1234562313]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company has previously conducted trials and received the approval by the Drug Controller General Of India in 2017 for its product APCEDEN (personalized dendritic cell-based immunotherapy). Being completely autologous in nature, it has been successfully infused to patients with an excellent safety profile and efficacy.

APAC Biotech’s present invention provides a composition comprising of a population of activated dendritic cells tutored in the lab to produce immunogens useful in the treatment of cancer. The invention also provides a method for producing a population of activated dendritic cells specific to a patient’s whole tumor protein. Most significantly, the procedures used to manufacture dendritic cells replicate the natural environment of the human host very closely. APAC Biotech’s technology, therefore, guarantees the highest quality of customized dendritic cells produced for clinical use and marketed at the lowest cost, as compared to any other biotech company globally.

APAC BIOTECH, in their continuous research for making cutting-edge technology feasible for all patients, has more patents lined up which will be eventually filed to other countries as well.

APAC BIOTECH’s new product is named LTR-MEMVAXRALEUCEL, which is a unique, advanced and never-been-used-before technology (licensed) based on homogenous loading of whole tumor amplified mRNA and whole tumor protein, specifically designed for Glioblastoma and Pancreatic Ductal Adenocarcinoma for which clinical trial is awaited, and APAC BIOTECH is in talks with various eminent hospitals and principal investigators to initiate the trial in India very soon.

"We are proud to acknowledge that APCEDEN is a completely Make in India product. With the Indian FDA approval and Indian patent, we hope to raise investments to expand our operations PAN India and help the cause of cancer treatment. We are also looking at global partners to expand our operations on a technology transfer basis," commented Mr. Arun Mehra, CEO.

argenx to report half year 2020 financial results and second quarter business update on July 30, 2020

On July 23, 2020 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, reported that it will host a conference call and audio webcast on Thursday, July 30, 2020 at 2:30 pm CET (8:30 am ET) to discuss its second quarter 2020 financial results and provide a business update (Press release, argenx, JUL 23, 2020, View Source [SID1234562297]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please select your phone number below and use the confirmation code 7470386. The webcast may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for 90 days following the call.

Phosplatin Therapeutics Receives Notice of US Patent Issuance for PT-112 as Therapeutic Agent for Treatment of Bone or Blood Cancers

On July 23, 2020 Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, reported that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,668,080, entitled: "Phosphaplatin Compounds as Therapeutics Agents for Treatment of Bone or Blood Cancers (Press release, Phosplatin, JUL 23, 2020, View Source [SID1234564994])." The granted claims are directed to the use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes, inclusive of the Company’s lead compound, PT-112, as therapeutic agents for the treatment of bone and blood cancers, such as multiple myeloma, or solid tumor cancers that metastasize to bone, such as metastatic castration resistant prostate cancer (mCRPC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This issuance marks an important additional step in strengthening the protection of our intellectual property for PT-112, as we continue to study it as both a monotherapy and in combination across a range of cancers, including mCRPC and multiple myeloma," said Robert Fallon, President and Chief Executive Officer of Phosplatin Therapeutics.

PT-112’s pleiotropic mode of action avoids the drug resistance mechanisms common to conventional anti-cancer therapy. Further, it leads to immunogenic cell death (ICD), a rare form of anti-cancer action that promotes an adaptive immune response to the tumor. PT-112 has been validated as an ICD-inducing agent, and also reported to induce durable responses in Phase I patients at soft tissue sites of disease, characteristic of immune involvement. The drug’s pyrophosphate moiety, additionally, is believed to be responsible for directing it at highest concentrations to the mineralized bone (osteotropism).

"Beyond its other features, PT-112’s osteotropism leads us to posit that it has attractive development opportunities related to bone site of disease," said Mr. Fallon. "This patent issuance allows us to pursue such development with added confidence."

About PT-112

PT-112 is the first small molecule conjugate of pyrophosphate developed in oncology therapeutics. PT-112 promotes immunogenic cell death (ICD), or the release of damage associated molecular patterns (DAMPs) that lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents a potential best-in-class small molecule inducer of this immunological form of cancer cell death, and is under Phase II development. The first-in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients, and won "Best Poster" at the ESMO (Free ESMO Whitepaper) 2018 Annual Congress within the Developmental Therapeutics category. The novelty of its pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in bone, or frequently lead to metastatic bone involvement, such as metastatic castrate-resistant prostate cancer (mCRPC). The first human clinical results in mCRPC were presented at the 2020 Genitourinary Cancers Symposium on February 13, 2020.

Synaffix Announces Third Deal Expansion by ADC Therapeutics

On July 23, 2020 Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, reported that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies (Press release, Synaffix, JUL 23, 2020, View Source [SID1234562267]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the expanded collaboration, ADC Therapeutics has been granted non-exclusive rights for two additional programs, which brings the total number of programs using Synaffix’ ADC technologies to five. ADC Therapeutics also gains access to the latest innovative extensions of Synaffix’ proprietary GlycoConnect platform, including DAR1 technology that enables stable attachment of just a single drug per antibody.

Synaffix is eligible to receive upfront, milestone and royalty payments tied to each program. Further financial details are not disclosed.

Peter van de Sande, CEO of Synaffix said:

"We are very pleased to see the rapid progression of ADC Therapeutics’ programs that have been developed using our GlycoConnect ADC technology platform, and the multiple collaboration expansions that have followed our original agreement.

"We look forward to continuing to work closely with the ADC Therapeutics team as they translate more product candidates using GlycoConnect into the clinic."

Synaffix entered into the original commercial license agreement with ADC Therapeutics in October 2016. ADC Therapeutics is responsible for the research, development, manufacturing and commercialization of any resulting ADC products, and Synaffix is responsible for the manufacturing of components specifically related to its proprietary ADC technologies.

BioCryst to Report Second Quarter 2020 Financial Results on August 6

On July 23, 2020 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020 (Press release, BioCryst Pharmaceuticals, JUL 23, 2020, https://ir.biocryst.com/news-releases/news-release-details/biocryst-report-second-quarter-2020-financial-results-august-6 [SID1234562298]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 5142479. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 5142479.